Germany · Delayed Price · Currency is EUR Northwest Biotherapeutics Statistics
Total Valuation
BST:NBYB has a market cap or net worth of EUR 310.15 million. The enterprise value is 377.83 million.
| Market Cap | 310.15M |
| Enterprise Value | 377.83M |
Important Dates
The last earnings date was Monday, August 11, 2025.
| Earnings Date | Aug 11, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 1.48B |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +14.25% |
| Shares Change (QoQ) | +5.79% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 1.37B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 332.94 |
| PB Ratio | -4.20 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -5.31 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -9.82 |
Financial Position
The company has a current ratio of 0.07
| Current Ratio | 0.07 |
| Quick Ratio | 0.05 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.55 |
| Interest Coverage | -8.18 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -141.48% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 120.26% |
| Revenue Per Employee | 37,262 |
| Profits Per Employee | -2.85M |
| Employee Count | 25 |
| Asset Turnover | 0.04 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -39.87% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -39.87% |
| 50-Day Moving Average | 0.22 |
| 200-Day Moving Average | 0.24 |
| Relative Strength Index (RSI) | 49.94 |
| Average Volume (20 Days) | 19,728 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 20.76 |
Income Statement
In the last 12 months, BST:NBYB had revenue of EUR 931,541 and -71.14 million in losses. Loss per share was -0.05.
| Revenue | 931,541 |
| Gross Profit | -28.39M |
| Operating Income | -55.68M |
| Pretax Income | -70.09M |
| Net Income | -71.14M |
| EBITDA | -54.17M |
| EBIT | -55.68M |
| Loss Per Share | -0.05 |
Balance Sheet
The company has 3.68 million in cash and 59.44 million in debt, giving a net cash position of -55.77 million.
| Cash & Cash Equivalents | 3.68M |
| Total Debt | 59.44M |
| Net Cash | -55.77M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -73.77M |
| Book Value Per Share | -0.06 |
| Working Capital | -66.22M |
Cash Flow
In the last 12 months, operating cash flow was -37.91 million and capital expenditures -554,327, giving a free cash flow of -38.46 million.
| Operating Cash Flow | -37.91M |
| Capital Expenditures | -554,327 |
| Free Cash Flow | -38.46M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | -5,977.15% |
| Pretax Margin | -7,524.50% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
BST:NBYB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -14.25% |
| Shareholder Yield | n/a |
| Earnings Yield | -22.94% |
| FCF Yield | -12.40% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BST:NBYB has an Altman Z-Score of -78.47 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -78.47 |
| Piotroski F-Score | 1 |